A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.
But Donald Trump's most impactful move could be to spearhead the world's first cancer vaccine. This week, amid a flurry of executive orders, the new president announced a $500billion venture he ...